USO1 promotes tumor progression via activating Erk pathway in multiple myeloma cells.
Jin Y et al. Biomed Pharmacother. 2016 Mar;78:264-71. doi: 10.1016/j.biopha.2016.01.012. Epub 2016 Feb 2.

Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats.
Al-Harbi NO et al. Toxicol Mech Methods. 2016 Feb 21:1-7. [Epub ahead of print].

Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma.
Ronchetti D et al. Oncotarget. 2016 Feb 17. doi: 10.18632/oncotarget.7442. [Epub ahead of print].

Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
Favreau M et al. Oncotarget. 2016 Feb 17. doi: 10.18632/oncotarget.7440. [Epub ahead of print].

Gamabufotalin triggers c-Myc degradation via induction of WWP2 in multiple myeloma cells.
Yu Z et al. Oncotarget. 2016 Feb 15. doi: 10.18632/oncotarget.7398. [Epub ahead of print].

The Impact of Mast Cell Density on the Progression of Bone Disease in Multiple Myeloma Patients.
Vyzoukaki R et al. Int Arch Allergy Immunol. 2016 Feb 20;168(4):263-268. [Epub ahead of print].

α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer.
Han Z et al. ChemMedChem. 2016 Feb 17. doi: 10.1002/cmdc.201500600. [Epub ahead of print].

Race-based differences in routine cytogenetic profiles of patients with multiple myeloma.
Blue BJ et al. Br J Haematol. 2016 Feb 16. doi: 10.1111/bjh.13950. [Epub ahead of print].

Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition.
Raab MS et al. Blood. 2016 Feb 16. pii: blood-2015-12-686782. [Epub ahead of print].

Lupeol Isolated from Sorbus commixta Suppresses 1α,25-(OH)2D3-Mediated Osteoclast Differentiation and Bone Loss in Vitro and in Vivo.
Im NK et al. J Nat Prod. 2016 Feb 16. [Epub ahead of print].

Calebin A downregulates osteoclastogenesis through suppression of RANKL signalling.
Tyagi AK et al. Arch Biochem Biophys. 2016 Feb 11;593:80-89. doi: 10.1016/ [Epub ahead of print].

Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma.
Perumal D et al. Cancer Res. 2016 Feb 12. [Epub ahead of print].

Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.
Lionetti M et al. Oncotarget. 2016 Feb 8. doi: 10.18632/oncotarget.7241. [Epub ahead of print].

Chromogranin A is preferentially cleaved into pro-angiogenic peptides in the bone marrow of multiple myeloma patients.
Bianco M et al. Cancer Res. 2016 Feb 11. pii: canres.1637.2015. [Epub ahead of print].

SGK kinase activity in multiple myeloma cells protects against ER stress apoptosis via a SEK-dependent mechanism.
Hoang B et al. Mol Cancer Res. 2016 Feb 11. pii: molcanres.0422.2015. [Epub ahead of print].

Chetomin, targeting HIF-1α/p300 complex, exhibits antitumour activity in multiple myeloma.
Viziteu E et al. Br J Cancer. 2016 Feb 11. doi: 10.1038/bjc.2016.20. [Epub ahead of print].

Exosomes promote bone marrow angiogenesis in hematologic neoplasia: the role of hypoxia.
Ohyashiki JH et al. Curr Opin Hematol. 2016 Feb 10. [Epub ahead of print].

Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma.
Nair S et al. N Engl J Med. 2016 Feb 11;374(6):555-61. doi: 10.1056/NEJMoa1508808.

Targeting vasculogenesis to prevent progression in multiple myeloma.
Moschetta M et al. Leukemia. 2016 Feb 3. doi: 10.1038/leu.2016.3. [Epub ahead of print].

Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
Drent E et al. Haematologica. 2016 Feb 8. pii: haematol.2015.137620. [Epub ahead of print].

Heparanase promotes myeloma progression by inducing mesenchymal features and motility of myeloma cells.
Li J et al. Oncotarget. 2016 Feb 3. doi: 10.18632/oncotarget.7170. [Epub ahead of print].

Reelin promotes the adhesion and drug resistance of multiple myeloma cells via integrin β1 signaling and STAT3.
Lin L et al. Oncotarget. 2016 Feb 3. doi: 10.18632/oncotarget.7151. [Epub ahead of print].

Impact of genes highly correlated with MMSET myeloma on survival of Non-MMSET myeloma patients.
Wu SP et al. Clin Cancer Res. 2016 Feb 4. pii: clincanres.2366.2015. [Epub ahead of print].

miR-137 suppresses the phosphorylation of AKT and improves the dexamethasone sensitivity in multiple myeloma cells via targeting MITF.
Zhang B et al. Curr Cancer Drug Targets. 2016 Feb 2. [Epub ahead of print].

Sponges against miR-19 and miR-155 reactivate the p53-Socs1 axis in hematopoietic cancers.
Mignacca L et al. Cytokine. 2016 Feb 1. pii: S1043-4666(16)30015-1. doi: 10.1016/j.cyto.2016.01.015. [Epub ahead of print].

Touch and Go -Nuclear proteolysis in the regulation of metabolic genes and cancer.
Maneix L et al. FEBS Lett. 2016 Feb 2. doi: 10.1002/1873-3468.12087. [Epub ahead of print].

Zoledronic acid induces dose-dependent increase of antigen-specific CD8 T-cell responses in combination with peptide/poly-IC vaccine.
Park HM et al. Vaccine. 2016 Jan 29. pii: S0264-410X(16)00070-0. doi: 10.1016/j.vaccine.2016.01.026. [Epub ahead of print].

Oxidative stress and proteasome inhibitors in multiple myeloma.
Lipchick BC et al. Pharmacol Res. 2016 Jan 29;105:210-215. doi: 10.1016/j.phrs.2016.01.029. [Epub ahead of print].

The ubiquitin ligase HERC4 mediates c-Maf ubiquitination and delays the growth of multiple myeloma xenografts in nude mice.
Zhang Z et al. Blood. 2016 Jan 29. pii: blood-2015-07-658203. [Epub ahead of print].

Aiolos collaborates with Blimp-1 to regulate the survival of multiple myeloma cells.
Hung KH et al. Cell Death Differ. 2016 Jan 29. doi: 10.1038/cdd.2015.167. [Epub ahead of print].